{"name":"Fulgent Pharma LLC.","slug":"fulgent-pharma-llc","ticker":"","exchange":"","domain":"fulgentpharmallc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FID007","genericName":"FID007","slug":"fid007","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"FID-022","genericName":"FID-022","slug":"fid-022","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"FID007","genericName":"FID007","slug":"fid007","phase":"phase_2","mechanism":"FID007 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes","Heart failure"],"catalyst":""},{"name":"FID-022","genericName":"FID-022","slug":"fid-022","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPWmEteFBnSmg4R2poWnQ4d2JHWDN2Um5OdW8ydFpnUHdraXN5R2ZyVngxOTJWUndHWm1YQ3VRNGJnSS1LZmFfVzdJRmtKdFQ5RDlqaGVOeEl1LWxzb2hVUXBaZ2ZVLVRNRVJWQ2lVbFNMU082blV0U0pTRzNaM2lPWVRSRWZaQjdWdkRWelFYOTd4dXhEU0Z2cTk1ZTdWMGZ5OHRzV1hhQlUxS0FPSUlCTFlOMXhwY0MzeF9QNFctOUpTUQ?oc=5","date":"2022-11-08","type":"deal","source":"Fierce Pharma","summary":"Plotting a Fulgent future, diagnostic business inks $100M deal to reunite with drug delivery sibling - Fierce Pharma","headline":"Plotting a Fulgent future, diagnostic business inks $100M deal to reunite with drug delivery sibling","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE95WHl1ZGJTanNRQjJ4RHh2M1Nrb0JFX1JwQ1NwczN5WW16MDdHYko3Q3F5TEdBOGpUektaT1ppbmQxdjhaa0dwM3NPY3NIekVRcGF2YWs5cjMwZEpSREhB?oc=5","date":"2022-02-24","type":"pipeline","source":"Nature","summary":"A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant - Nature","headline":"A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates again","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9ORklFYkNmVWxOMG5BTWFYTHN4OUw3STUwSFdSZXdObElrcFBKRHFuR2lpekwtek1leE1kSGIybm5xXzJULUxqTHlaandDdVhyeDBXS0JRcWlydnVPTmNN?oc=5","date":"2022-01-19","type":"pipeline","source":"Nature","summary":"A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs - Nature","headline":"A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell re","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}